Supplementary Data from Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

• DOI: 10.1158/1078-0432.22472513
• Publication Date: 2023-04-01T01:30:25Z
• Authors: Lindsey E. Roeker; Christopher P. Fox; Toby A. Eyre; Danielle M. Brander; John N. Allan; Stephen J. Schuster; Chadi Nabhan; Brian T. Hill; Nirav N. Shah; Frederick Lansigan; Maryam Yazdy; Bruce D. Cheson; Nicole Lamanna; Arun K. Singavi; Catherine C. Coombs; Paul M. Barr; Alan P. Skarbnik; Mazyar Shadman; Chaitra S. Ujjani; Hande H. Tuncer; Allison M. Winter; Joanna Rhodes; Colleen Dorsey; Hannah Morse; Charlene Kabel; John M. Pagel; Annalynn M. Williams; Ryan Jacobs; Andre Goy; Sivraj Muralikris...; Laurie Pearson; Andrea Sitlinger; Neil Bailey; Anna Schuh; Amy A. Kirkwood; Anthony R. Mato

<p>Supplemental Figure 1.</p>